Survey of Ophthalmology
Volume 54, Issue 6 , Pages 686-696 , November 2009

Amniotic Membrane Transplantation as a New Therapy for the Acute Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  • Elizabeth Shay, BS

      Affiliations

    • TissueTech Inc., Miami, Florida, USA
    • ,
  • Ahmad Kheirkhah, MD

      Affiliations

    • Ocular Surface Center and Ocular Surface Research and Education Foundation, Miami, Florida, USA
    • ,
  • Lingyi Liang, MD

      Affiliations

    • Ocular Surface Center and Ocular Surface Research and Education Foundation, Miami, Florida, USA
    • ,
  • Hossam Sheha, MD, PhD

      Affiliations

    • Ocular Surface Center and Ocular Surface Research and Education Foundation, Miami, Florida, USA
    • ,
  • Darren G. Gregory, MD

      Affiliations

    • Department of Ophthalmology, Rocky Mountain Lions Eye Institute, Denver, Colorado, USA
    • ,
  • Scheffer C.G. Tseng, MD, PhD

      Affiliations

    • TissueTech Inc., Miami, Florida, USA
    • Ocular Surface Center and Ocular Surface Research and Education Foundation, Miami, Florida, USA
    • Corresponding Author InformationReprint address: Scheffer C.G. Tseng, MD, PhD, Ocular Surface Center and Ocular Surface Research & Education Foundation, 7000 SW 97th Avenue, Suite 213. Miami, FL 33173.

References 

  1. Adds PJ, Hunt CJ, Dart JK. Amniotic membrane grafts, “fresh” or frozen? A clinical and in vitro comparison. Br J Ophthalmol. 2001;85:905–907
  2. Aihara Y, Ito R, Ito S, et al. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatr Int. 2007 Oct;49(5):659–662
  3. Arevalo JM, Lorente JA, Gonzalez–Herrada C, Jimenez–Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48(3):473–478
  4. Arora R, Mehta D, Jain V. Amniotic membrane transplantation in acute chemical burns. Eye. 2005 Mar;19(3):273–278
  5. Arstikaitis MJ. Ocular aftermath of Stevens–Johnson syndrome. Arch Ophthalmol. 1973 Nov;90(5):376–379
  6. Ashby DW, Lazar T. Erythema multiforme exudativum major (Stevens-Johnson syndrome). Lancet. 1951;1(20):1091–1095
  7. Belfort R, de SM, Whitcup SM, et al. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS. Cornea. 1991;10(6):536–538
  8. Bottinger LE, Strandberg I, Westerholm B. Drug-induced febrile mucocutaneous syndrome: with a review of literature. Acta Med Scand. 1975;198:229–233
  9. Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocular Surface. 2004;2(3):201–211
  10. Brilakis HS, Palmon FE, Webster GF, Holland EJ. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. In:  Krachmer JH,  Mannis MJ,  Holland EJ editor. Cornea. ed. 2,. Philadelphia: Mosby; 2005;p. 691–702
  11. Burman S, Tejwani S, Vemuganti GK, et al. Ophthalmic applications of preserved human amniotic membrane: a review of current indications. Cell Tissue Bank. 2004;5(3):161–175
  12. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–47
  13. Chang YS, Huang FC, Tseng SH, et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26(2):123–129
  14. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241–253
  15. Chen J, Zhou S, Huang T, et al. [A clinical study on fresh amniotic membrane transplantation for treatment of severe ocular surface disorders at acute inflammatory and cicatricial stage]. Zhonghua Yan Ke Za Zhi. 2000;36(1):13–17
  16. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112(5):904–912
  17. Dohlman CH, Doughman DJ. The Stevens-Johnson Syndrome. Trans New Orleans Acad Ophthalmol. 1972;24:236–252
  18. Dua HS, Azuara-Blanco A. Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol. 1999;83:414–419
  19. Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Surv Ophthalmol. 2004 Jan;49(1):51–77
  20. Dua HS, Jagjit SS, Azuara-Blanco A, Gupta P. Limbal stem cell deficiency: concept, aetiology, clinical presentation, diagnosis and management. Indian J Ophthalmol. 2000;48:83–92
  21. Espana EM, Di Pascuale M, Grueterich M, et al. Keratolimbal allograft in corneal reconstruction. Eye. 2004;18(4):406–417
  22. French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Allergol Int. 2006;55(1):9–16
  23. Grueterich M, Espana EM, Tseng SCG. Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. Surv Ophthalmol. 2003;48:631–646
  24. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008;40(2):129–138
  25. Howard GM. The Stevens-Johnson syndrome. Ocular prognosis and treatment. Am J Ophthalmol. 1963;55:893–900
  26. John T, Foulks GN, John ME, et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology. 2002;109(2):351–360
  27. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97(3):272–280
  28. Kheirkhah A, Johnson DA, Paranjpe DR, et al. Temporary sutureless amniotic membrane patch for acute alkaline burns. Arch Ophthalmol. 2008;126(8):1059–1066
  29. Kim JS, Kim JC, Na BK, et al. Amniotic membrane patching promotes healing and inhibits protease activity on wound healing following acute corneal alkali burns. Exp Eye Res. 2000;70:329–337
  30. Kobayashi A, Shirao Y, Yoshita T, et al. Temporary amniotic membrane patching for acute chemical burns. Eye. 2003;17:149–158
  31. Kobayashi A, Yoshita T, Sugiyama K, et al. Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement. Ophthalmology. 2006;113(1):126–132
  32. Koizumi N, Inatomi T, Suzuki T, et al. Cultivated corneal epithelial stem cell transplantation in ocular surface disorders. Ophthalmology. 2001;108:1569–1574
  33. Lavker RM, Tseng SC, Sun TT. Corneal epithelial stem cells at the limbus: looking at some old problems from a new angle. Exp Eye Res. 2004;78(3):433–446
  34. Lee NJ, Wang SJ, Durairaj KK, et al. Increased expression of transforming growth factor-beta1, acidic fibroblast growth factor, and basic fibroblast growth factor in fetal versus adult fibroblast cell lines. Laryngoscope. 2000;110(4):616–619
  35. Lee SH, Tseng SCG. Amniotic membrane transplantation for persistent epithelial defects with ulceration. Am J Ophthalmol. 1997;123:303–312
  36. Lerner LH, Qureshi AA, Reddy BV, Lerner EA. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol. 2000;114(1):196–199
  37. Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94(4):419–436
  38. Liu C, Paul B, Tandon R, et al. The osteo-odonto-keratoprosthesis (OOKP). Semin Ophthalmol. 2005;20(2):113–128
  39. Luo HY, Peng SM, Wang YJ. [Fresh amniotic membrane transplantation for ocular surface diseases]. Di Yi Jun Yi Da Xue Xue Bao. 2003;23(5):488–489
  40. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68(11):355–361
  41. Meller D, Pires RT, Mack RJ, et al. Amniotic membrane transplantation for acute chemical or thermal burns. Ophthalmology. 2000;107(5):980–989
  42. Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg. 1996;15(4):236–243
  43. Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology. 1990;97(7):939–952
  44. Muqit MM, Ellingham RB, Daniel C. Technique of amniotic membrane transplant dressing in the management of acute Stevens-Johnson syndrome. Br J Ophthalmol. 2007;91(11):1536
  45. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol. 1990;126(8):1103–1104
  46. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118(4):728–733
  47. Ostler HB, Conant MA, Groundwater J. Lyell's disease, the Stevens-Johnson syndrome, and exfoliative dermatitis. Trans Am Acad Ophthalmol. Otolaryngol. 1970;74(6):1254–1265
  48. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130(5):605–608
  49. Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol. 2005;136(3):205–216
  50. Patz A. Ocular involvement in erythema multiforme. Arch Ophthalmol. 1950;43(2):244–256
  51. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134(4):710–714
  52. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1):155–161
  53. Power WJ, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669–1676
  54. Prabhasawat P, Kosrirukvongs P, Booranapong W, Vajaradul Y. Amniotic membrane transplantation for ocular surface reconstruction. J Med Assoc Thai. 2001;84(5):705–718
  55. Ralph RA. Conjunctival goblet cell density in normal subjects and in dry eye syndromes. Invest Ophthalmol. 1975;14(4):299–302
  56. Raviglione MC, Pablos-Mendez A, Battan R. Clinical features and management of severe dermatological reactions to drugs. Drug Saf. 1990;5(1):39–64
  57. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6):28S–30S
  58. Sangwan VS, Burman S, Tejwani S, et al. Amniotic membrane transplantation: a review of current indications in the management of ophthalmic disorders. Indian J Ophthalmol. 2007;55(4):251–260
  59. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens–Johnson syndrome. Am J Ophthalmol. 2008;145(3):438–444
  60. Scheinfeld N. A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine. J Drugs Dermatol. 2007;6(3):352–355
  61. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58(1):33–40
  62. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127(6):839–842
  63. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Anti-inflammatory effects of amniotic membrane transplantation in ocular surface disorders. Cornea. 2001;20(4):408–413
  64. Sippel KC, Ma JJK, Foster CS. Amniotic membrane surgery. Curr Opin Ophthalmol. 2001;12:269–281
  65. Solomon A, Ellies P, Anderson DF, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology. 2002;109(6):1159–1166
  66. Solomon A, Espana EM, Tseng SCG. Amniotic membrane transplantation for reconstruction of the conjunctival fornices. Ophthalmology. 2003;110:93–100
  67. Solomon A, Meller D, Prabhasawat P, et al. Amniotic membrane grafts for nontraumatic corneal perforations, descemetoceles, and deep ulcers. Ophthalmology. 2002;109(4):694–703
  68. Sridhar MS, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation in acute chemical and thermal injury. Am J Ophthalmol. 2000;130:134–137
  69. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and opthalmitis. Report of two cases in children. Am J Dis Child. 1922;24(6):526–533
  70. Tandon A, Cackett P, Mulvihill A, Fleck B. Amniotic membrane grafting for conjunctival and lid surface disease in the acute phase of toxic epidermal necrolysis. J AAPOS. 2007;11(6):612–613
  71. Tejwani S, Kolari RS, Sangwan VS, Rao GN. Role of amniotic membrane graft for ocular chemical and thermal injuries. Cornea. 2007;26(1):21–26
  72. Tonnesen MG, Soter NA. Erythema multiforme. J Am Acad Dermatol. 1979;1(4):357–364
  73. Tseng SC. Amniotic membrane transplantation for ocular surface reconstruction. Biosci Rep. 2001;21(4):481–489
  74. Tseng SCG. Regulation and clinical implications of corneal epithelial stem cells. Mol Biol Rep. 1996;23:47–58
  75. Tseng SCG, Chen JJY, Huang AJW, et al. Classification of conjunctival surgeries for corneal disease based on stem cell concept. Clin North Am Ophthalmol. 1990;3:595–610
  76. Tseng SCG, Di Pascuale MA, Liu DZ, et al. Intraoperative mitomycin C and amniotic membrane transplantation for fornix reconstruction in severe cicatricial ocular surface diseases. Ophthalmology. 2005;112:896–903
  77. Tseng SCG, Espana EM, Kawakita T, et al. How does amniotic membrane work?. Ocular Surface. 2004;2(3):177–187
  78. Tseng SCG, Li DQ, Ma X. Suppression of transforming growth factor isoforms, TGF–b receptor II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999;179:325–335
  79. Ueta M, Kweon MN, Sano Y, et al. Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction. Clin Exp Immunol. 2002;129(3):464–470
  80. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490–493
  81. Viard-Leveugle I, Bullani RR, Meda P, et al. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem. 2003;278(18):16183–16188
  82. Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol. 1984;120(6):721–726
  83. Wright P, Collin JR. The ocular complications of erythema multiforme (Stevens Johnson syndrome) and their management. Trans Ophthalmol Soc UK. 1983;103(Pt 3):338–341
  84. Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001;20(1):19–23
  85. Yang R, Wang F, Sun N. [Application of fresh amniotic membrane transplantation in treatment of stenosis of conjunctival sac]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2004;18(4):277–280
  86. Yetiv JZ, Bianchine JR, Owen JA. Etiologic factors of the Stevens-Johnson syndrome. South Med J. 1980;73(5):599–602
  87. Zhao F, Xu W, Guan J. [Clinical observation on fresh amniotic membrane transplantation for treatment of recurrent pterygium]. Yan Ke Xue Bao. 2002;18(4):220–222
  88. Zhou S, Chen J, Fung B, Chen L. Fresh amniotic membrane transplantation combined lamellar keratoplasty for patients with recurrent Mooren's ulcer. Yan Ke Xue Bao. 2003;19(1):1–5
  89. Zhou S, Chen J, Xu L, et al. Fresh amniotic membrane transplantation for conjunctival surface reconstruction. Yan Ke Xue Bao. 1999;15(3):169–173
  90. Zhou S, Yuan J, Chen L, Chen J. [Fresh versus preserved amniotic membrane transplantation for conjunctival surface reconstruction]. Yan Ke Xue Bao. 2008;24(1):39–43

 Dr Tseng has obtained a patent for the method of preparation and clinical uses of amniotic membrane and has licensed the right to Bio-Tissue, which procures, processes, and distributes preserved amniotic membrane for clinical and research uses. The other authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. Dr. Ahmad Kheirkhah is a recipient of Joseph Swiger and Eye Foundation of America Fellowship from Ocular Surface Research and Education Foundation, Miami, FL. Dr. Lingyi Liang received the Exchange Scholarship Grant for PhD candidates from the Scholarship Council of China.

PII: S0039-6257(09)00119-2

doi: 10.1016/j.survophthal.2009.03.004

Survey of Ophthalmology
Volume 54, Issue 6 , Pages 686-696 , November 2009

Article Tools

* Image Usage & Resolution